March 2023 – New Guidance on the use of “spare” anaphylaxis auto-injectors
The MHRA has issued new guidance, clarifying that a school’s “spare” adrenaline auto-injector(s) can, in principle, be used for the purpose of saving a life for a pupil or other person not known by the school to be at risk of anaphylaxis (and thus does not have medical authorisation/consent in place for the spare device).
This might be, for example, a child presenting for the first time with anaphylaxis due to an unrecognised allergy.
Click the link to read the full document: https://www.gov.uk/government/publications/clarification-of-adrenaline-autoinjector-guidance-for-schools
NEW LEGISLATION ALLOWS “SPARE” EMERGENCY ADRENALINE AUTO- INJECTORS IN SCHOOLS
In October 2017 legislation changed allowing schools in the UK to keep spare adrenaline auto-injectors (AAIs) for emergency use. AAIs deliver a potentially life-saving dose of adrenaline in the event of a severe allergic reaction (anaphylaxis).
A working group, made up of representatives from the Anaphylaxis Campaign, Allergy UK, the British Society for Allergy & Clinical Immunology (BSACI), the British Paediatric Allergy Immunity and Infection Group (BPAIIG), and the Royal College of Paediatrics and Child Health (RCPCH), campaigned for the Government to amend the Human Medicines Act to allow schools to buy AAIs from a pharmaceutical supplier, without prescription, for use in emergencies. The working group and their respective organisations have welcomed the new legislation which allows school staff to administer an emergency AAI to any child who has been assessed as being at risk of anaphylaxis.
Over 1600 parents/carers and 800 teachers completed a survey in 2015 to assess backing for the campaign and over 99% of parents and 96% of teachers supported the proposal. The survey formed a crucial part of the evidence presented to the Department of Health. A public consultation conducted by the Department of Health this year also found overwhelming support for a change in the law to allow schools to hold spare AAIs, without a prescription, for use in emergencies.
A joint statement from the five organisations says:
“The rise in food allergy among young people is posing a significant risk for schools who can be faced with a life-threatening situation requiring urgent action. One in five fatal food-allergic reactions in children happen at school. Schools can now purchase the first-line treatment for anaphylaxis, without a prescription. While not compulsory, we hope many schools will take advantage of this change as part of their duty of care tp those children who are at risk of anaphylaxis. This is likely to increase awareness and highlight the need for staff to be trained to recognise and treat anaphylaxis in school.”